اکنون در دسترس! پژوهش تلگرام ۲۰۲۵ — مهمترین بینشهای سال 
JAMA (Journal of the American Medical Association)
رفتن به کانال در Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
نمایش بیشتر📈 تحلیل کانال تلگرام JAMA (Journal of the American Medical Association)
کانال JAMA (Journal of the American Medical Association) (@jamaupdates) در بخش زبانی انگلیسی بازیگری فعال است. در حال حاضر جامعه شامل 15 120 مشترک است و جایگاه 1 626 را در دسته پزشکی و رتبه 2 540 را در منطقه الولايات المتحدة الأمريكية دارد.
📊 شاخصهای مخاطب و پویایی
از زمان ایجاد در невідомо، پروژه رشد سریعی داشته و 15 120 مشترک جذب کرده است.
بر اساس آخرین دادهها در تاریخ 05 ژوئن, 2026، کانال فعالیت پایداری دارد. در ۳۰ روز گذشته تغییر اعضا برابر 569 و در ۲۴ ساعت گذشته برابر 25 بوده و همچنان دسترسی گستردهای حفظ شده است.
- وضعیت تأیید: تأیید نشده
- نرخ تعامل (ER): میانگین تعامل مخاطب 4.40% است و در ۲۴ ساعت نخست پس از انتشار، محتوا معمولاً 1.99% واکنش نسبت به کل مشترکان کسب میکند.
- دسترسی پستها: هر پست به طور میانگین 664 بازدید دریافت میکند. در اولین روز معمولاً 300 بازدید جمعآوری میشود.
- واکنشها و تعامل: مخاطبان بهطور فعال حمایت میکنند؛ میانگین واکنش به هر پست 1 است.
- علایق موضوعی: محتوا بر موضوعات کلیدی مانند patient, disease, treatment, drug, guideline تمرکز دارد.
📝 توضیح و سیاست محتوایی
نویسنده این فضا را محل بیان دیدگاههای شخصی توصیف میکند:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
به لطف بهروزرسانیهای پرتکرار (آخرین داده در تاریخ 07 ژوئن, 2026)، کانال همواره بهروز و دارای دسترسی بالاست. تحلیلها نشان میدهد مخاطبان بهطور فعال با محتوا تعامل دارند و آن را به نقطه اثرگذاری مهم در دسته پزشکی تبدیل کردهاند.
15 120
مشترکین
+2524 ساعت
+1287 روز
+56930 روز
در حال بارگیری داده...
کانالهای مشابه
ابر برچسبها
اشارات ورودی و خروجی
---
---
---
---
---
---
جذب مشترکین
ژوئن '26
ژوئن '26
+106
در 0 کانالها
مه '26
+584
در 0 کانالها
Get PRO
آوریل '26
+437
در 0 کانالها
Get PRO
مارس '26
+217
در 0 کانالها
Get PRO
فوریه '26
+247
در 0 کانالها
Get PRO
ژانویه '26
+321
در 0 کانالها
Get PRO
دسامبر '25
+277
در 0 کانالها
Get PRO
نوامبر '25
+366
در 2 کانالها
Get PRO
اکتبر '25
+164
در 0 کانالها
Get PRO
سپتامبر '25
+12
در 0 کانالها
Get PRO
اوت '25
+29
در 0 کانالها
Get PRO
ژوئیه '25
+30
در 0 کانالها
Get PRO
ژوئن '25
+17
در 0 کانالها
Get PRO
مه '25
+9
در 0 کانالها
Get PRO
آوریل '25
+5
در 0 کانالها
Get PRO
مارس '25
+17
در 0 کانالها
Get PRO
فوریه '25
+12
در 0 کانالها
Get PRO
ژانویه '25
+18
در 1 کانالها
Get PRO
دسامبر '24
+237
در 0 کانالها
Get PRO
نوامبر '24
+1 122
در 0 کانالها
Get PRO
اکتبر '24
+1 120
در 0 کانالها
Get PRO
سپتامبر '24
+1 527
در 1 کانالها
Get PRO
اوت '24
+1 128
در 1 کانالها
Get PRO
ژوئیه '24
+1 216
در 0 کانالها
Get PRO
ژوئن '24
+781
در 1 کانالها
Get PRO
مه '24
+797
در 1 کانالها
Get PRO
آوریل '24
+808
در 1 کانالها
Get PRO
مارس '24
+821
در 2 کانالها
Get PRO
فوریه '24
+753
در 1 کانالها
Get PRO
ژانویه '24
+768
در 0 کانالها
Get PRO
دسامبر '23
+716
در 1 کانالها
Get PRO
نوامبر '23
+96
در 1 کانالها
Get PRO
اکتبر '23
+86
در 0 کانالها
Get PRO
سپتامبر '23
+73
در 0 کانالها
Get PRO
اوت '23
+90
در 0 کانالها
Get PRO
ژوئیه '23
+107
در 0 کانالها
Get PRO
ژوئن '23
+105
در 0 کانالها
Get PRO
مه '23
+169
در 0 کانالها
Get PRO
آوریل '23
+128
در 0 کانالها
Get PRO
مارس '23
+84
در 0 کانالها
Get PRO
فوریه '23
+75
در 0 کانالها
Get PRO
ژانویه '23
+71
در 0 کانالها
Get PRO
دسامبر '22
+74
در 0 کانالها
Get PRO
نوامبر '22
+149
در 0 کانالها
Get PRO
اکتبر '22
+90
در 0 کانالها
Get PRO
سپتامبر '22
+138
در 0 کانالها
Get PRO
اوت '22
+77
در 0 کانالها
Get PRO
ژوئیه '22
+50
در 0 کانالها
Get PRO
ژوئن '22
+96
در 0 کانالها
Get PRO
مه '22
+75
در 0 کانالها
Get PRO
آوریل '22
+80
در 0 کانالها
Get PRO
مارس '22
+65
در 0 کانالها
Get PRO
فوریه '22
+26
در 0 کانالها
Get PRO
ژانویه '22
+56
در 0 کانالها
Get PRO
دسامبر '21
+44
در 0 کانالها
Get PRO
نوامبر '21
+39
در 0 کانالها
Get PRO
اکتبر '21
+61
در 0 کانالها
Get PRO
سپتامبر '21
+66
در 0 کانالها
Get PRO
اوت '21
+65
در 0 کانالها
Get PRO
ژوئیه '21
+96
در 0 کانالها
Get PRO
ژوئن '21
+120
در 0 کانالها
Get PRO
مه '21
+130
در 0 کانالها
Get PRO
آوریل '21
+812
در 0 کانالها
| تاریخ | رشد مشترکین | اشارات | کانالها | |
| 07 ژوئن | +8 | |||
| 06 ژوئن | +13 | |||
| 05 ژوئن | +25 | |||
| 04 ژوئن | +22 | |||
| 03 ژوئن | +9 | |||
| 02 ژوئن | +19 | |||
| 01 ژوئن | +10 |
پستهای کانال
Insulin Costs and Use After the Inflation Reduction Act Out-of-Pocket Cap
https://jamanetwork.com/journals/jama/fullarticle/2850128
This interrupted time series analysis uses Medicare Part D data from January 2021 through December 2023 to measure changes in insulin cost and use after the Inflation Reduction Act $35 cap on out-of-pocket insulin costs, overall and for insulin users with previously high out-of-pocket cost.
| 2 | Insulin Cost Caps and Pharmacoequity
https://jamanetwork.com/journals/jama/fullarticle/2850129
Diabetes incidence is rising in the US, with more than 40 million US residents living with this condition. Diabetes morbidity and mortality are unequally distributed, and new diagnoses are higher among American Indian/Alaska Native, Black, and Hispanic adults, compared with White adults. Managing prescription medications is critical to reducing diabetes morbidity, as is controlling risk factors and associated comorbid conditions. However, the cost of pharmacologic therapy has increased substantially, driven in part by the growing use of newer glucose-lowering agents. The high cost of these medications comprises a substantial portion of diabetes-related health care expenditure for individuals with diabetes and may result in restrictive coverage by health plans insuring enrollees with diabetes, further limiting access to care. The out-of-pocket costs faced by patients are particularly burdensome, because patients also face the consequences of adverse downstream outcomes that result from reduced medication adherence due to costs. | 265 |
| 3 | Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850123
This study evaluated whether finerenone, a nonsteroidal mineralocorticoid receptor antagonist, can slow loss of kidney function in patients with glomerular diseases. | 511 |
| 4 | Finerenone for CKD Due to Glomerular Diseases
https://jamanetwork.com/journals/jama/fullarticle/2850124
This exploratory analysis of a randomized clinical trial evaluates the efficacy and safety of finerenone in reducing chronic kidney disease of participants with glomerular diseases, including disease subtype. | 515 |
| 5 | Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850098
This study investigated whether low-dose rivaroxaban reduces major adverse cardiovascular events compared with placebo in adults with advanced chronic kidney disease (CKD) stage 4 or 5, including those receiving dialysis. | 673 |
| 6 | Measured and Estimated Glomerular Filtration Rates and Risk of Adverse Health Outcomes
https://jamanetwork.com/journals/jama/fullarticle/2850099
This study evaluates associations between major clinical outcomes and measured glomerular filtration rate (GFR), estimated GFR (eGFR) for plasma creatinine, eGFR for cystatin C, and eGFR for a combination of plasma creatinine and cystatin C in a large cohort of patients in Sweden. | 618 |
| 7 | Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
https://jamanetwork.com/journals/jama/fullarticle/2850100
This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events. | 565 |
| 8 | Precision, Pragmatism, and Emerging Paradigms in Determining Kidney Filtration Function
https://jamanetwork.com/journals/jama/fullarticle/2850101
Chronic kidney disease (CKD) is defined largely by glomerular filtration rate (GFR), a construct with broad clinical implications. Guidelines from Kidney Disease: Improving Global Outcomes categorize CKD stages in adults according to GFR thresholds and albuminuria to assess risk of kidney failure. These CKD categories help clinicians dose medications with a narrow therapeutic window (eg, chemotherapy, antimicrobials), screen for metabolic complications of kidney dysfunction, determine eligibility for kidney transplant, and evaluate risks of death and cardiovascular disease events. Yet a patient’s GFR assessment depends on which test is ordered. In routine clinical practice, GFR is estimated (eGFR) rather than measured (mGFR). Small differences between estimates for GFR that fall close to the thresholds for CKD categorization can reclassify a patient’s disease status, thereby influencing diagnostic testing and treatment decisions. Measured GFR is the reference standard, but it is burdensome, time consuming, and not widely available. Thus, most clinical studies rely on eGFR to determine the associations of CKD with kidney failure, cardiovascular disease, and death. | 501 |
| 9 | Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease
https://jamanetwork.com/journals/jama/fullarticle/2850102
Cardiovascular disease accounts for approximately half of all deaths among patients with advanced chronic kidney disease (CKD), including those with kidney failure requiring dialysis. Despite this disproportionate burden, effective strategies to prevent and treat cardiovascular disease in this population remain limited. Trials conducted in broader populations, including patients with mild to moderate CKD, have suggested that low-dose rivaroxaban may confer cardiovascular protection. However, extrapolating these findings to advanced CKD is problematic given the distinct biology of uremia and other CKD-specific mechanisms in advanced CKD that heighten cardiovascular risk and increase susceptibility to bleeding. Few large-scale trials have studied interventions to reduce the high incidence of cardiovascular events in patients with advanced CKD or kidney failure requiring dialysis. | 399 |
| 10 | Coffee, Tea, and Cognitive Function
https://jamanetwork.com/journals/jama/fullarticle/2849857
To the Editor A recent study reported higher caffeinated coffee and tea intake was associated with lower dementia risk and modestly better cognitive performance in participants from the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). In adjusted models, participants in the highest vs lowest quartile of caffeinated coffee consumption had a hazard ratio (HR) of 0.82 (95% CI, 0.76-0.89) for dementia, with the most pronounced difference at a moderate intake of approximately 2 to 3 cups per day. We propose that, in addition to neurobiological effects of caffeine, part of this association may reflect more socially active lifestyles among regular coffee drinkers, which themselves protect against dementia. | 450 |
| 11 | Point-of-Care Ultrasound for the Diagnosis of Pneumonia
https://jamanetwork.com/journals/jama/fullarticle/2849858
This JAMA Insights explores the use of point-of-care ultrasound as a less expensive, more accessible alternative to chest radiography and computed tomography for diagnosing community-acquired pneumonia. | 677 |
| 12 | Trials and Health Policy
https://jamanetwork.com/journals/jama/fullarticle/2849859
Seldom are health policy decisions guided solely—or even primarily—by evidence from clinical trials. Indeed, there may be an inherent mismatch between the broad scope and rapid speed of most policy decisions and the deliberate specificity and methodical pace of traditional trial research. Policymakers often adopt or fund interventions for broad populations based on incomplete information, and under time pressure, budgetary constraints, and competing political demands. Clinical trialists, in contrast, may focus on generating internally valid answers to highly specific questions under carefully controlled conditions, a process that can take years of planning, data collection, and analysis. Not surprisingly, policymakers may perceive that the evidence generated by trials is too limited and arrives too late to guide many of the real-world decisions they make, while trialists may lament that sweeping policy actions are taken without robust experimental evidence demonstrating their effects. | 385 |
| 13 | Incentivizing Kidney Transplants While Safeguarding Equity
https://jamanetwork.com/journals/jama/fullarticle/2849850
This Viewpoint discusses the US Centers for Medicare & Medicaid Services’ Increasing Organ Transplant Access Model and outlines pathways to monitor the implementation of the model to ensure equitable access for all patients. | 345 |
| 14 | Controversies About Osteoporotic Fracture Prevention Strategies
https://jamanetwork.com/journals/jama/fullarticle/2849851
This Viewpoint considers controversies regarding osteoporotic fracture prevention strategies, noting that some currently available medications, including estrogen, are underused and poorly understood. | 357 |
| 15 | Patient Information: Ebola
https://jamanetwork.com/journals/jama/fullarticle/2849890
This JAMA Patient Page describes how Ebola is transmitted, how common the infection is and where outbreaks have occurred, risk factors and symptoms, and how it is diagnosed and treated. | 357 |
| 16 | Notes From the Far End of the Stethoscope
https://jamanetwork.com/journals/jamacardiology/fullarticle/2849967
This essay describes the author’s experience going from clinician to patient and back again. | 449 |
| 17 | Error in Results
https://jamanetwork.com/journals/jamacardiology/fullarticle/2849968
The Original Investigation titled “Chronic Kidney Disease Prevalence and Awareness Among US Adults,” published on November 8, 2025, was corrected to fix an error in the awareness of chronic kidney disease diagnosis among Hispanic adults reported in the Results; the correct values are 12.5% (95% CI, 10.5%-14.4%). This article was corrected online. | 508 |
| 18 | Finerenone Across Cardiovascular-Kidney-Metabolic Syndrome Stages
https://jamanetwork.com/journals/jamacardiology/fullarticle/2849969
This study evaluates the efficacy and safety of finerenone across cardiovascular-kidney-metabolic stages, and examines the effects of finerenone on cardiovascular-kidney-metabolic syndrome progression and regression over time. | 470 |
| 19 | Precardioversion Heart Rhythm Monitoring Using Smartphone PPG
https://jamanetwork.com/journals/jamacardiology/fullarticle/2849970
This randomized clinical trial evaluates the efficacy and feasibility of smartphone-based precardioversion rhythm monitoring vs standard of care. | 449 |
| 20 | Standard-Dose Tenecteplase v Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion
https://jamanetwork.com/journals/jamaneurology/fullarticle/2849793
This randomized clinical trial attempts to determine whether standard-dose tenecteplase at 0.25 mg/kg achieves a higher rate of recanalization on the initial angiogram than low-dose alteplase at 0.6 mg/kg in patients scheduled for mechanical thrombectomy. | 664 |
